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146Objectives: Recent evidence indicated that the use of a bioprosthesis in young patients at first-time aortic valve
replacement (AVR) is associated with an increased reoperation risk, but not with an increase in long-term mor-
tality, when compared with the use of a mechanical valve. However, at reoperative AVR, follow-up data by pros-
thesis type have been lacking from the literature. Therefore, we examined long-term survival and valve-related
complications according to the type of prosthesis used at reoperative AVR.
Methods: We studied 437 patients who underwent reoperative AVR, at a mean age of 58.6  14.2 years, for
failure of a previously implanted aortic valve prosthesis. Thirty-day mortality at reoperative AVR was 6%
(n ¼ 27). A bioprosthesis was used in 135 (31%) patients. Patients were subsequently followed up for
a mean of 7.6  6.8 years after reoperative AVR.
Results: The use of a bioprosthesis at reoperative AVR was not associated with impaired survival on adjusted
analysis (hazard ratio [HR], 0.8 0.4; P¼ .6). Freedom from thromboembolism, and endocarditis were similar
between valve types (both P>.05); however, late postoperative major hemorrhage occurred only in patients who
received a mechanical prosthesis at reoperative AVR. Risk factors for third-time AVR included the use of a bio-
prosthesis (HR, 14.0) and younger age (HR, 1.05 per decreasing year) at reoperative AVR (both P< .001).
Thirty-day mortality of third-time AVR was 4% (n ¼ 1/27).
Conclusions: At reoperative AVR, the use of a bioprosthesis is associated with equivalent long-term survival
compared with a mechanical prosthesis. Patients who receive a bioprosthesis at reoperative AVR are less likely
to experience major hemorrhage but more likely to require third-time AVR, albeit with an acceptable third-time
perioperative mortality risk. Therefore, the patient’s informed preferences regarding prosthesis choice should
prevail, even in a reoperative context. (J Thorac Cardiovasc Surg 2012;144:146-51)Earn CME credits at
http://cme.ctsnetjournals.org
Long-term outcomes after aortic valve replacement (AVR)
with either a biological or a mechanical prosthesis have
been widely described.1-5 Prospective and retrospective
data have indicated that structural valve deterioration
and reoperation are much more common with
bioprostheses.1-5 However, mechanical prostheses require
long-term anticoagulation and are associated with higher
rates of hemorrhage and thromboembolism.1-5 Notably,
patients with a mechanical prosthesis have greater
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The Journal of Thoracic and Cardiovascular Surgfor warfarin, and their quality of life scores are generally
lower than those of patients with a bioprosthesis.6
Recent very long-term data indicated that although reop-
eration risk is greater for young patients who select a bio-
prosthesis for first-time AVR, long-term survival is
equivalent.7 At reoperative AVR, however, data reporting
on the outcomes of prosthesis selection have been lacking
from the literature. With no data to rely on, clinical acumen
and common sense have often led to mechanical prostheses
being favored in younger patients to minimize the likeli-
hood of a third-time heart valve operation.7
Objective information on this issue is needed inasmuch
as young patients increasingly opt for a bioprosthesis at
initial AVR and may wish to prolong their oral
anticoagulation-free lifestyle, even after reoperation. Fur-
thermore, high-risk reoperation for a failed aortic valve
bioprosthesis may now be handled, in select cases, by
valve-in-valve transcatheter aortic valve implantation.8
Therefore, data comparing the use of a bioprosthesis with
a mechanical prosthesis at reoperative AVR performed
surgically are in our opinion relevant and needed, not
only for the cardiology and cardiac surgery communities,
but also for valve patients and their families.
In this regard, we performed a long-term, ambispective
follow-up study involving 437 patients who underwentery c July 2012
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ine and compare the outcomes of biological versus mechan-
ical prosthesis use at reoperative AVR with regard to
long-term survival and valve-related complications.
METHODS
Ethics Approval
The University of Ottawa Heart Institute has an existing approval from
its institutional research ethics board to anonymously publish data that are
prospectively collected before and after heart valve replacement. As such,
individual patient consent was waived.
Patients and Follow-up
Between 1971 and 2008, 437 patients underwent reoperative AVR for
a failed aortic valve prosthesis at the University of Ottawa Heart Institute,
Ottawa, Canada, and were prospectively followed up at the University of
Ottawa Heart Valve Clinic. This included annual assessments for
prosthesis-related complications, as outlined by the ‘‘Guidelines for Re-
portingMortality andMorbidity after Cardiac Valve Interventions.’’9 In ad-
dition to valve clinic visits, follow-up information was supplemented by
telephone interviews and electronic medical records. Follow-up after reo-
perative AVR amounted to a mean of 7.6  6.8 years and extended up to
31.8 years. In 34 patients, most of whom lived outside Ottawa, the
follow-up interval was 1month or less from hospital discharge. On average,
patients who survived beyond hospital discharge were seen over 10.7 9.1
postoperative clinic visits (median, 9 postoperative clinic visits).
Statistical Analysis
Baseline characteristics were compared between patients who received
a bioprosthesis versus a mechanical prosthesis at reoperative AVR. Data
distributions were assessed with a Shapiro-Wilk test and/or with a histo-
gram, as appropriate. Continuous variables were assessed by using the Stu-
dent t test when data were normally distributed and a Wilcoxon rank sum
test when data were skewed.
The Kaplan-Meier method was used to compare survival and freedom
from valve-related complications between valve types.9 Risk factors associ-
ated with survival and third-time AVR were determined by using separate
semiparametricmultivariable Cox proportional hazardsmodels. The propor-
tional hazards assumption was verified with Schoenfeld residuals, and the
models were made by incorporating the following: (1) variables with P 
.10 on log–rank testing, (2) patient and surgical characteristics that differed
between biological andmechanical prosthesis groups, and (3) previously de-
scribed risk factors for latemortality in patients who have undergone AVR.10
All covariates were entered into the final model simultaneously. In addition,
Cox proportional hazards models for long-term survival and third-time AVR
were repeated to include only the 355 patients who received valves currently
available in North America. In this study, contemporary bioprostheses in-
cluded the use of an autograft/homograft, Carpentier-Edwards Perimount
(Baxter Healthcare Corp, Irvine, Calif), Medtronic Hancock II (Medtronic,
Inc, Minneapolis, Minn), and the Medtronic Mosaic (Medtronic, Inc). Con-
temporary mechanical prostheses included the Medtronic Hall (Medtronic,
Inc), On-X (On-X Life Technologies, Austin, Tex), and the St Jude Medical
Standard bileaflet valve (St JudeMedical, Inc, St Paul, Minn). Multivariable
modeling was not performed for the outcomes of hemorrhage, thromboem-
bolism, or endocarditis owing to the low number of events.The Journal of Thoracic and CaRESULTS
Patient Characteristics at Reoperation
Entire cohort. Table 1 describes the characteristics of pa-
tients who received a bioprosthesis or a mechanical prosthe-
sis at the time of reoperative AVR. Patients who received
a bioprosthesis at reoperative AVR were older (62.9 
13.8 years vs 56.7  14.0 years; P<.001), more likely in
New York Heart Association III or IV preoperatively
(P¼ .03), and more likely to undergo concomitant coronary
artery bypass grafting at reoperative AVR (P ¼ .003) than
patients who received amechanical prosthesis. Themean in-
terval from initial AVR to reoperative AVR was 7.2  5.2
years (median, 7.1 years). The valve prosthesis implanted
at initial AVR, outlined in Table 2, had predominantly
been a bioprosthesis (bioprosthesis n¼ 345, 79%; mechan-
ical prosthesis n ¼ 92, 21%). The Ionescu-Shiley valve
(Shiley, Inc, Irvine, Calif ) had been implanted in 228
(52.2%) patients at initial AVR. These patients with a prior
Ionescu-Shiley aortic valve subsequently underwent reoper-
ativeAVR at an older age comparedwith the rest of the study
cohort (60.5  12.3 years vs 56.5  17.4; P ¼ .003). At re-
operative AVR, however, the Ionescu-Shiley valve was used
in 42 (9.6%) patients. Valve prostheses implanted at the
time of reoperative AVR are shown in Table 3.
Contemporary prostheses only. Patients who received
a contemporary bioprosthesis at reoperative AVR were
also older (66.1  12.5 years vs 57.0  14.0 years;
P<.001), more likely in New York Heart Association class
III or IV preoperatively (P ¼ .04), and more likely to un-
dergo concomitant coronary artery bypass grafting at reo-
perative AVR (P < .001) than patients who received
a contemporary mechanical prosthesis.
Survival
Entire cohort. There were 161 deaths in the patient popu-
lation during follow-up. Causes of death included cancer
(n¼ 15), cerebrovascular accident (n¼ 6), congestive heart
failure (n¼ 22), multiorgan failure (n¼ 10), myocardial in-
farction (n ¼ 10), pneumonia or respiratory failure (n ¼ 7),
prosthetic valve endocarditis (n ¼ 7), renal failure (n ¼ 3),
structural valve deterioration (n ¼ 1), other noncardiac
causes (n ¼ 14), and unknown causes (n ¼ 66). Causes of
death according to prosthesis type at reoperative AVR are
shown in Table 4.
Unadjusted 15-year survival after reoperative AVR was
35.5%  6.6% with a bioprosthesis versus 53.8% 
3.9%with a mechanical prosthesis (P¼ .05) (Figure 1). Af-
ter adjusting for the older age of bioprostheses patients, con-
comitant coronary artery bypass grafting, and preoperative
left ventricular function, prosthetic valve type was not asso-
ciated with survival (hazard ratio [HR], 0.8; bioprostheses
versus mechanical prostheses 95% confidence interval
[CI], 0.3-2.1; P¼ .6). The use of an Ionescu-Shiley prosthe-
sis at reoperative AVR was also not associated with survivalrdiovascular Surgery c Volume 144, Number 1 147
TABLE 1. Patient characteristics at reoperation
Bioprosthesis
use at
reoperative
AVR (n ¼ 135)
Mechanical
prosthesis use at
reoperative AVR
(n ¼ 302)
P
value
Age at reoperation (y) 62.9  13.8 56.7  14.0 <.001
Atrial fibrillation, n* 8 (6%) 16 (5%) .8
Female gender, n 39 (29%) 86 (28%) .9
LV grade, ny .6
I 42 (31%) 96 (32%)
II 19 (14%) 71 (24%)
III 23 (17%) 55 (18%)
IV 51 (38%) 80 (26%)
NYHA III-IV, n 91 (67%) 167 (55%) .03
Prior aortic bioprosthesis, n 107 (79%) 238 (79%) .9
Concomitant CABG
at reoperative AVR, n
.003
0 100 (74%) 260 (86%)
1 23 (17%) 25 (8%)
2 10 (7%) 13 (4%)
3 2 (2%) 4 (1%)
Reoperative 30-day
mortality, n
10 (7%) 17 (6%) .5
AVR, Aortic valve replacement; LV, left ventricle; NYHA, New York Heart Associa-
tion functional class; CABG, coronary artery bypass grafting. *Includes permanent
and known paroxysmal atrial fibrillation preoperatively. yLV grade I ¼ ejection frac-
tion> 50%; grade II ¼ ejection fraction 35%-50%; grade III ¼ ejection fraction
20%-34%; grade IV ¼ ejection fraction<20%.
TABLE 3. Valve prostheses implanted at reoperative AVR
No. (N ¼ 437)
Percent
of total
Bioprosthesis
Edwards Lifesciences Perimount*,y 25 5.7
Autograft/homografty 16 3.7
Ionescu-Shileyz 42 9.6
Medtronic Hancock Modified Orificex 14 3.2
Medtronic Hancock IIy,x 29 6.6
Medtronic Intactk 6 1.4
Medtronic Mosaicy,{ 3 0.7
Mechanical prosthesis
Bj€ork-Shiley* 10 2.3
CarboMedicsk 53 12.1
Harken 2 0.5
Lillehei-Kaster 8 1.8
Medtronic Hally,x 109 25.0
On-Xy,{ 32 7.3
St Jude Medicaly,# 88 20.1
*Edwards Lifesciences, Baxter Healthcare Corp, Irvine, Calif. yContemporary bio-
prostheses. zShiley Laboratories, Irvine, Calif. xMedtronic Inc, Minneapolis, Minn.
kCarboMedics Inc, Sorin Group, Austin, Tex. {On-X Life Technologies Inc, Austin,
Tex. #St Jude Medical, Brussels, Belgium.
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factor associated with survival on multivariable analysis
(HR, 1.08 per increasing year; 95% CI, 1.03-1.14;
P ¼ .003) (Table 5).
TABLE 2. Failed aortic valve prostheses explanted at reoperative
AVR
No. (N ¼ 437)
Percent
of total
Bioprosthesis
Edwards Lifesciences Perimount*,y 8 1.8
Autograft/homografty 37 8.5
Ionescu-Shiley Standardz 228 52.2
Medtronic Hancock Modified Orificex 31 7.1
Medtronic Hancock IIy,x 26 5.9
Medtronic Intactk 10 2.3
Medtronic Mosaicy,{ 3 0.7
Other bioprosthesis 2 0.5
Mechanical prosthesis
Bj€ork-Shiley* 2 0.5
CarboMedicsk 8 1.8
Harken 27 6.2
Lillehei-Kaster 9 2.1
Medtronic Hally,x 23 5.3
On-Xy,{ 8 1.8
St Jude Medicaly,# 15 3.4
*Edwards Lifesciences, Baxter Healthcare Corp, Irvine, Calif. yContemporary bio-
prostheses. zShiley Laboratories, Irvine, Calif. xMedtronic Inc, Minneapolis, Minn.
kCarboMedics Inc, Sorin Group, Austin, Tex. {On-X Life Technologies Inc, Austin,
Tex. #St Jude Medical, Brussels, Belgium.
148 The Journal of Thoracic and Cardiovascular SurgContemporary prostheses only. Equivalent results were
observed when analyses were restricted to patients who re-
ceived currently available valve prostheses. In them, age
(HR, 1.07 per increasing year; 95% CI, 1.01-1.14;
P ¼ .02), but not bioprosthesis use (HR, 0.4; 95% CI,
0.1-3.5; P ¼ .4), was again associated with decreased sur-
vival. Unadjusted 15-year survival after reoperative AVR
with a contemporary prosthesis was 15.7%  12.4% with
a bioprosthesis versus 52.3%  4.1% with a mechanical
prosthesis (P ¼ .1).
During follow-up, there were 116 deaths in patients who
received a contemporary prosthesis. Causes of death in-
cluded cancer (n ¼ 14), cerebrovascular accident (n ¼ 4),TABLE 4. Causes of death
Cause of death
Bioprosthesis:
Use at reoperative
AVR (n ¼ 135)
Mechanical
prosthesis:
Use at reoperative
AVR (N ¼ 302)
Cancer 6 9
Cerebrovascular accident 0 6
Congestive heart failure 5 17
Multiorgan failure 2 8
Myocardial infarction 6 4
Pneumonia or respiratory
failure
3 4
Prosthetic valve endocarditis 5 2
Renal failure 0 3
Structural valve deterioration 1 0
Other noncardiac causes 4 10
Unknown causes 17 49
AVR, Aortic valve replacement.
ery c July 2012
FIGURE 1. Survival after reoperative aortic valve replacement (AVR).
Unadjusted all-cause survival from the time of reoperative AVR, according
to the prosthesis type used at reoperative AVR. In total, 161 deaths occurred
in the cohort (51 deaths among patients who received a bioprosthesis and
110 deaths among patients who received a mechanical prosthesis).
FIGURE 2. Freedom from third-time aortic valve replacement (AVR).
Freedom from third-time AVR after reoperative AVR for a failed aortic
valve prosthesis. Twenty-seven third-time AVRs occurred in this cohort
(17 third-time AVRs in patients who received a bioprosthesis at reoperative
AVR and 10 third-time AVRs in patients who received a mechanical pros-
thesis at reoperative AVR). The mean interval to third-time AVR was 6.9
5.5 years.
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Dcongestive heart failure (n¼ 16), multiorgan failure (n¼ 8),
myocardial infarction (n ¼ 4), pneumonia or respiratory
failure (n ¼ 7), prosthetic valve endocarditis (n ¼ 2), renal
failure (n ¼ 3), other noncardiac causes (n ¼ 12), and un-
known causes (n ¼ 46).
Third-Time AVR
Entire cohort. Twenty-seven patients subsequently under-
went third-time AVR (6%), with an operative mortality of
4% (n ¼ 1/27). Freedom from third-time AVR at 10 and
15 years was 72.0% 7.1% and 43.6% 15.1%with a bi-
oprosthesis, compared with 96.4%  1.4% and 96.4% TABLE 5. Risk factors associated with long-term survival after
reoperative AVR
HR 95% CI P value
Univariate risk factors
Age at reoperation (per increasing year) 1.05 1.03–1.06 <.001
Bioprosthesis use at reoperative AVR 1.4 1.0–2.0 .05
Concomitant CABG at reoperative
AVR*
1.6 1.0–2.4 .05
Decade of studyy 0.7–1.2 0.3–2.0 .5
Ionescu-Shiley prosthesis use at
reoperative AVR
1.1 0.7–1.7 .8
LV grade (per increasing grade)z 1.2 0.9–1.7 .2
Multivariable risk factors
Age at reoperation (per increasing year) 1.08 1.03–1.14 .003
Bioprosthesis use at reoperative AVR 0.8 0.3–2.1 .6
AVR, Aortic valve replacement;HR, hazard ratio; CI, confidence interval;CABG, cor-
onary artery bypass grafting; LV, left ventricle. *Entered into the univariate and mul-
tivariable model as a dichotomous variable (ie, CABG yes/no). yThis study was
conducted between 1971-2008. The study interval was divided into decades (A-D).
Each decade was included in a Cox model assessing overall survival. The range of
hazard ratios for all decades (A-D) is the one reported in the table, along with the
range of 95% confidence intervals. The reported P value is the lowest one of all
the decades. No decade of operation was associated with a statistically significant ef-
fect on survival. zLV grade I ¼ ejection fraction>50%; grade II ¼ ejection fraction
35%-50%; grade III ¼ ejection fraction 20%-34%; grade IV ¼ ejection
fraction<20%.
The Journal of Thoracic and Ca1.4% with a mechanical prosthesis (P<.001) (Figure 2).
Patients who were older (HR, 0.95 per increasing year;
P<.001) or female (HR, 0.3; P ¼ .04) were less likely to
undergo third-time AVR (Table 6). Of the 27 patients who
underwent third-time AVR, 17 had a bioprosthesis, of
whom 12 had received an Ionescu-Shiley prosthesis at reo-
perative AVR. The use of an Ionescu-Shiley valve at reoper-
ative AVR was associated with an increased need for
subsequent third-time AVR (HR, 10.1; 95% CI, 4.7-21.5;
P<.001).
Contemporary prostheses only. Eleven (3%) patients
who received contemporary prostheses at reoperative
AVR subsequently underwent third-time AVR at a mean
of 6.3  6.2 years, with no perioperative mortality in this
group. Freedom from third-time AVR at 10 years wasTABLE 6. Risk factors associated with third-time AVR
HR 95% CI P value
Univariate risk factors
Age at reoperation (per increasing year) 0.96 0.93– 0.98 .001
Bioprosthesis use at reoperative AVR 7.6 3.3–17.1 < .001
Concomitant CABG at reoperative
AVR*
0.3 0.1–1.9 .1
Female gender 0.4 0.2–1.2 .1
LV grade (per increasing grade)y 1.6 0.7–3.9 .3
Multivariable risk factors
Age at reoperation (per increasing year) 0.95 0.93–0.98 < .001
Bioprosthesis use at reoperative AVR 14.0 5.7–33.6 < .001
Concomitant CABG at reoperative AVR* 0.2 0.1–1.5 .1
Female gender 0.3 0.1–0.9 .04
AVR, Aortic valve replacement;HR, hazard ratio; CI, confidence interval;CABG, cor-
onary artery bypass grafting; LV, left ventricle. *Entered into the univariate and mul-
tivariable model as a dichotomous variable (ie, CABG yes/no). yLV grade I¼ ejection
fraction>50%; grade II¼ ejection fraction 35%-50%; grade III¼ ejection fraction
20%-34%; grade IV ¼ ejection fraction<20%.
rdiovascular Surgery c Volume 144, Number 1 149
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96.1% 1.5%with a contemporary mechanical prosthesis
(P ¼ .6). Patients who were older at reoperative AVR (HR,
0.95 per increasing year; P ¼ .007) were less likely to un-
dergo subsequent third-time AVR.
Hemorrhage and Thromboembolism
Entire cohort. All patients who received a mechanical
prosthesis at reoperative AVR were given warfarin for anti-
coagulation postoperatively. Of the 135 patients who re-
ceived a bioprosthesis at reoperative AVR, 16 (11%) were
given warfarin postoperatively. Twenty-eight hemorrhagic
or thromboembolic events were observed in 27 patients dur-
ing follow-up, of whom 7 had received bioprostheses and 20
had received mechanical prostheses at reoperative AVR.
Ten-year unadjusted freedom from thromboembolism was
94.2%  3.2% for bioprostheses and 97.0%  1.3% for
mechanical prostheses (P ¼ .4). Ten-year unadjusted free-
dom from major hemorrhage in this cohort was 100% for
bioprostheses and 16.7% 15.2% for mechanical prosthe-
ses. The lifetime cumulative incidence for hemorrhage or
thromboembolism was 7.1% for bioprostheses and 18.3%
for mechanical prostheses.
Contemporary prostheses only. No hemorrhagic events
were observed in the bioprosthesis group, whereas 7 hemor-
rhagic events were observed in the mechanical prosthesis
group at a median of 4.5 years. Ten-year unadjusted free-
dom from thromboembolism was 91.7%  8.0% for con-
temporary bioprostheses and 96.3%  1.4% for
contemporary mechanical prostheses (P¼ .8). Ten-year un-
adjusted freedom from hemorrhage in this cohort was
100% for contemporary bioprostheses and 16.7% 
15.2% for contemporary mechanical prostheses.
Endocarditis
Entire cohort. Prosthetic valve endocarditis developed af-
ter reoperative AVR in 12 patients. Valve type was not asso-
ciated with endocarditis: 15-year freedom from
endocarditis was 92.6%  3.0% for bioprostheses versus
97.8%  1.0% for mechanical prostheses (P ¼ .2).
Contemporary prostheses only. Prosthetic valve endo-
carditis developed after reoperative AVR with a contempo-
rary prosthesis in 7 patients. Fifteen-year freedom from
endocarditis was 93.7% 4.3% for contemporary biopros-
theses versus 98.1% 1.0% for contemporary mechanical
prostheses (P ¼ .3).
DISCUSSION
In this study, we describe the outcomes of a large cohort
of patients who underwent reoperative AVR for a failed aor-
tic prosthesis. We compared the outcomes of patients who
received either a biological or a mechanical prosthesis at
the time of reoperative AVR in terms of long-term survival
and valve-related complications.9150 The Journal of Thoracic and Cardiovascular SurgPatients in this study were relatively young; nevertheless,
only one third had normal left ventricular function at reo-
perative AVR. The 30-day mortality of this cohort com-
pared favorably with that of other series describing
reoperative valve surgery.10-15 Reported 30-day mortality
for reoperative AVR has ranged from 5% to 15.3% in the
literature,10-13,15 which is comparable with series
describing first-time AVR.1,13 Although the risk of 30-day
mortality with reoperative AVR depends on patient and sur-
gical factors,12 other data have also suggested that reopera-
tion after bioprosthetic AVR may be performed with
acceptable perioperative morbidity and mortality, even in
elderly patients.16 However, those studies did not describe
the long-term outcomes of reoperative AVR or examine
the implications of selecting a biological prosthesis versus
a mechanical prosthesis at reoperative AVR.
In the present study, long-term survival was not associ-
ated with prosthesis type, although patients who received
a bioprosthesis at the time of reoperative AVR were more
likely to undergo third-time AVR. Our data suggest that pa-
tients whowish to continue their warfarin-free lifestyle may
do so by selecting a bioprosthesis at reoperative AVR, with-
out significantly impairing their long-term survival, albeit
with a higher risk of subsequent third-time AVR. Although
mechanical aortic valve prostheses offer excellent durabil-
ity,17,18 the lifetime cumulative risk of hemorrhage
and thromboembolism increases with the duration of
implantation.6 Moreover, patients taking warfarin long-
term after mechanical AVR have greater disease perception
and generally experience lower quality of life relative to pa-
tients who underwent AVR with a bioprosthesis.6 To our
knowledge, no other large study has described the late out-
comes of reoperative AVR and examined the implications
of prosthesis type, thus limiting comparisons of our study’s
findings to the existing literature.
Although patients in the present series who received
a bioprosthesis at reoperation were older than those who
received a mechanical prosthesis, freedom from thrombo-
embolism and endocarditis were comparable between
valve types. Only patients who received a mechanical
valve at reoperative AVR, however, were noted to experi-
ence hemorrhage during follow-up. Overall, 119 of the
135 patients who received a bioprostheses at reoperative
AVR were not managed on postoperative warfarin. The
low anticoagulation rate is the most likely explanation
for the lack of hemorrhage events in the bioprosthesis
group inasmuch as warfarin therapy is a known risk factor
for bleeding.19 Bioprosthesis use at reoperative AVR was
associated with the need for subsequent third-time AVR.
Notably, third-time AVR was subsequently performed in
27 (6%) patients with a perioperative mortality of 4%,
suggesting that patients undergoing third-time AVR may
have perioperative survival that is comparable with that
of first-time AVR.20ery c July 2012
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In this study, the decision to implant a bioprosthesis or
mechanical prosthesis was not randomized. Attempts
were made to control for differences in patient groups; how-
ever, the possibility of bias and unknown confounding fac-
tors remains. Some of the valves implanted in this cohort are
no longer commercially available. The Ionescu-Shiley and
the Bj€ork-Shiley valves had durability problems that may
have influenced outcomes with those prostheses.21-23
Although we repeated the analysis to include patients who
received currently available valve prostheses and found
similar results, these subcohort data are less powered and
may not be generalizable to the current generation of
heart valves. Overall, no difference in adjusted long-term
survival, unadjusted thromboembolism, or unadjusted en-
docarditis was observed between valve types, but it is pos-
sible that a difference might have been observed with
greater patient numbers and/or longer follow-up. Long-
term data concerning international normalized ratios are
also unknown.ACONCLUSIONS
At reoperative AVR, the use of a bioprosthesis is associ-
ated with equivalent long-term survival compared with
a mechanical prosthesis. Patients who receive a bioprosthe-
sis at reoperative AVR are more likely to require third-time
AVR, with an acceptable third-time AVR perioperative
mortality risk. Therefore, the patient’s informed prefer-
ences regarding the prosthesis choice should prevail, even
in a reoperative context.
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